Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsGreg Rhee, PhD, FACE
Associate Professor Adjunct in PsychiatryDownloadHi-Res Photo
About
Copy Link
Titles
Associate Professor Adjunct in Psychiatry
Biography
Greg Rhee, PhD, FACE, is Associate Professor of Medicine (Psychiatry) and Public Health (Epidemiology and Biostatistics). He is a pharmaco-epidemiologist and mental health services researcher studying access to care, quality of care, and clinical and patient-reported outcomes in patients with psychiatric and/or substance use disorders. His current research focuses on mood disorders, dementias, and suicide/suicidal behaviors as well as cannabis and opioids.
As an accredited professional statistician (PStat®) certified by the American Statistical Association, his expertise is grounded in (1) population-based observational studies using large databases; (2) systematic reviews and meta-analyses of existing studies; and (3) analyses of clinical trial data. In particular, he has extensive knowledge and experience with administrative claims data (e.g., Medicare and Medicaid), national health and healthcare survey data, and other data sources including electronic health records (e.g., Epic® database from Yale-New Haven Health), RCT data, and mortality data. He also investigates long-term comparative effectiveness and cost-effectiveness of pharmacological and non-pharmacological interventions for psychiatric and/or substance use disorders.
He has 250+ peer-reviewed research articles published in highly respected medical, psychiatric, and healthcare policy journals, such as Lancet, Lancet Neurology, JAMA, JAMA Psychiatry, and American Journal of Psychiatry. He has also been a successful Principal Investigator or Co-Investigator on multiple research projects funded by federal agencies, including Agency for Healthcare Research and Quality (AHRQ), Food and Drug Administration (FDA), and National Institutes of Health (NIH).
Outside Yale Psychiatry, he also serves as an Investigator at the VA Connecticut Healthcare System VISN 1 MIRECC and as a Senior Investigator at the Institute for Health Metrics and Evaluation (IHME).
Last Updated on March 22, 2025.
Departments & Organizations
- All Institutions
- Yale Depression Research Program
Education & Training
- NIH Postdoctoral Fellowship
- Yale University School of Medicine (2019)
- PhD
- University of Minnesota, Twin Cities (2017)
- MA
- The University of Chicago (2011)
- AB
- Emory University (2008)
Research
Copy Link
Overview
Medical Research Interests
Delivery of Health Care; Epidemiologic Methods; Geriatric Psychiatry; Health Services Research; Mental Disorders; Meta-Analysis; Network Meta-Analysis; Population Surveillance; Psychotropic Drugs; Substance-Related Disorders; United States Food and Drug Administration
Public Health Interests
Mental Health; Pharmaceuticals and Medical Devices; Health Equity, Disparities, Social Determinants and Justice; Health Policy; Aging
ORCID
0000-0003-4961-3361
Research at a Glance
Yale Co-Authors
Frequent collaborators of Greg Rhee's published research.
Publications Timeline
A big-picture view of Greg Rhee's research output by year.
Research Interests
Research topics Greg Rhee is interested in exploring.
Samuel Wilkinson, MD
Joseph Ross, MD, MHS
Robert Rosenheck, MD
John Havlik, MD, MBA
Sina Nikayin, MD
Gerard Sanacora, PhD, MD
162Publications
3,940Citations
Substance-Related Disorders
Mental Disorders
Psychotropic Drugs
United States Food and Drug Administration
Delivery of Health Care
Publications
2026
Effect of Ketamine on Reward Processing in Depressive Disorders: A Systematic Review of Neuroimaging Studies.
Faisal H, Le G, Kwan A, Wong S, Cheung W, Dri C, Cao B, Rhee T, Bargiota S, Lo H, Shen B, Guillen-Burgos H, McIntyre R. Effect of Ketamine on Reward Processing in Depressive Disorders: A Systematic Review of Neuroimaging Studies. CNS Spectrums 2026, 1-36. PMID: 41804256, DOI: 10.1017/s109285292610087x.Peer-Reviewed Original ResearchAltmetricInsufficient Sleep Among US Adolescents Across Behavioral Risk Groups
Bommersbach T, Olfson M, Rhee T. Insufficient Sleep Among US Adolescents Across Behavioral Risk Groups. JAMA: The Journal Of The American Medical Association 2026, 335 PMID: 41770537, PMCID: PMC12954592, DOI: 10.1001/jama.2026.1417.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAssociation of Recent and Past Homelessness with Health-Related Quality of Life among US Adults
Lo E, Rhee T, Rosenheck R. Association of Recent and Past Homelessness with Health-Related Quality of Life among US Adults. Psychiatric Quarterly 2026, 1-19. PMID: 41758416, DOI: 10.1007/s11126-026-10258-7.Peer-Reviewed Original ResearchConceptsHealth-related quality of lifeQuality Adjusted Life YearsHealth-related qualityNo history of homelessnessHistory of homelessnessQuality of lifeUS adultsPhysical health-related quality of lifeMeasures of health-related quality of lifeHomeless groupHomelessnessMental HRQOL scoresSample of US adultsPhysical health scoresEQ-5D utility valuesMental comorbiditiesAdjusted Life YearsNo historySF-12HRQoL scoresHealth scoresSociodemographic characteristicsEQ-5DLife yearsConfounding factorsAssociation of Multimodal Cannabis Use with Adverse Events among Adolescents and Young Adults
Bommersbach T, Olfson M, Rhee T. Association of Multimodal Cannabis Use with Adverse Events among Adolescents and Young Adults. American Journal Of Preventive Medicine 2026, 108313. PMID: 41698445, DOI: 10.1016/j.amepre.2026.108313.Peer-Reviewed Original ResearchConceptsPast-year cannabis useCannabis useUse disorderAdverse eventsCannabis use disorderCannabis use frequencyAcademic performanceSubstance use disordersYoung adultsSevere mental illnessCannabis-related harmsNational Survey of Drug Use and HealthPoor academic performanceDepressive episodeCannabis usersSuicide attemptsNational surveySuicidal thoughtsDrug Use and HealthMultivariable-adjusted analysesMental illnessCannabisCannabis productsDelinquent behaviorPast-yearThe effect of GLP-1 receptor agonists on autophagy: insights gathered from research evaluating neurodegenerative disorders with these agents
Sioufi M, Heroiu I, Wong S, Le G, Dri C, Zheng Y, Teopiz K, Rhee T, Lo H, Guillen-Burgos H, McIntyre R. The effect of GLP-1 receptor agonists on autophagy: insights gathered from research evaluating neurodegenerative disorders with these agents. Acta Neuropsychiatrica 2026, 38: e24. PMID: 41684077, DOI: 10.1017/neu.2026.10060.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsCardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease
Xu T, Wong S, Le G, Dri C, Teopiz K, Lu A, Lee S, Rhee T, Yin L, Bargiota S, Ho R, McIntyre R. Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease. Pharmacopsychiatry 2026, 59: 74-87. PMID: 41643722, DOI: 10.1055/a-2794-6487.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsValvular heart diseaseLysergic acid diethylamideAcid diethylamideCardiac valvulopathyHeart diseaseAssociated with valvular abnormalitiesDrug-induced valvular heart diseaseSignaling pathwaySystematic reviewClinical casesFunctional evidenceFibrotic signaling pathwaysValvular abnormalitiesIn vivo studiesPreclinical dataEntactogen 3,4-methylenedioxymethamphetaminePreclinical evidenceCardiac consequencesFibrotic changesValvulopathyReceptor activationDownstream signalingInterstitial cellsReceptor signalingValvular tissueEfficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson’s disease: a Bayesian network meta-analysis
Shim S, Jung Y, Kwon K, Rhee T, Lee S. Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson’s disease: a Bayesian network meta-analysis. Frontiers In Neurology 2026, 17: 1753555. PMID: 41716552, PMCID: PMC12913192, DOI: 10.3389/fneur.2026.1753555.Peer-Reviewed Original ResearchAltmetricConceptsCatechol-O-methyltransferase inhibitorBayesian Network Meta-AnalysisCatechol-O-methyltransferaseNetwork Meta-AnalysisMonoamine oxidase-BNon-motor symptomsStandardized mean differenceMeta-analysisQuality of lifeParkinson's diseaseMonoamine oxidase-B inhibitorIndividualized treatment approachCumulative ranking curveComprehensive literature searchProbability of benefitRasagiline monotherapyRandomized Controlled TrialsManagement of Parkinson's diseaseEmbase databasesFollow-upCochrane LibraryPatientsSUCRA rankingControlled TrialsMean differenceInterpreting the Signal Beyond the Trend: Response to Hanyu
Bommersbach T, Olfson M, Rhee T. Interpreting the Signal Beyond the Trend: Response to Hanyu. American Journal Of Psychiatry 2026, 183: 145-146. PMID: 41620814, DOI: 10.1176/appi.ajp.20251328.Peer-Reviewed Original ResearchIs the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?
Lu A, Xu H, Le G, Dri C, Wong S, Ho R, Cao B, Lo H, Rhee T, Yin L, Guillen-Burgos H, McIntyre R. Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms? European Psychiatry 2026, 69: e24. PMID: 41607072, PMCID: PMC12925689, DOI: 10.1192/j.eurpsy.2026.10157.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTreatment-resistant depressionAntidepressant effectsAntidepressant efficacyEffects of ketamineOpioid systemOpioid receptor subtypesPartial mediation effectAntidepressant efficacy of ketamineAnimal models of depressionAntidepressant effects of ketamineInconsistent attenuationSustained antidepressant effectsKetamine's antidepressant effectsModel of depressionReceptor subtypesEfficacy of ketamineOpioid receptor antagonistContext-dependent modulationAntidepressant doseKetamine responseKetamine effectsPreclinical studiesEsketamineAnimal modelsReceptor antagonismInnovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012-2024.
Havlik J, Isaac S, Radovan C, Ostacher M, Smith D, Rhee T. Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012-2024. The Journal Of Clinical Psychiatry 2026, 87 PMID: 41532845, DOI: 10.4088/jcp.25m16063.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPsychiatric drug developmentFirst-in-classWHO Model ListDrug developmentPsychiatric drugsPriority review statusMethod:Global burdenModel List of Essential MedicinesClinical usefulness rateGlobal burden of mental illnessClinical impactOrphan drug designationBurden of mental illnessProportion of drugsPrimary outcomeWHO Model List of Essential MedicinesTherapeutic approachesTherapeutic benefitPsychiatric indicationsDrug AdministrationClinical utilityObservational studySecondary measuresDrug
Academic Achievements & Community Involvement
Copy Link
Activities
activity Journal of Clinical Psychiatry
06/01/2022 - PresentJournal ServiceEditorial Board Memberactivity Depression and Anxiety
10/01/2022 - PresentJournal ServiceAssociate Editoractivity American Journal of Geriatric Psychiatry
2023 - PresentJournal ServiceEditorial Board Memberactivity National Institutes of Health Center for Scientific Review (CSR) - Study Section
2023 - PresentPeer Review Groups and Grant Study SectionsCommittee Member
Honors
honor Delta Omega Honorary Society in Public Health
05/05/2023International AwardDelta Omega (Faculty Mentor)honor Fellow
10/29/2022International AwardAmerican College of EpidemiologyDetailsUnited Stateshonor NIMH Advanced Research Institute (ARI) in Aging and Mental Health
02/01/2021National AwardNational Institute of Mental HealthDetailsUnited Stateshonor Research Career Institute in Mental Health of Aging (CIMA) Award
06/25/2019National AwardNational Institute of Mental HealthDetailsUnited Stateshonor Travel Fellowship
06/25/2019National AwardAssociation for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA)DetailsUnited States
News
Copy Link
News
- March 04, 2026Source: JAMA
Insufficient Sleep Among US Adolescents Across Behavioral Risk Groups
- December 18, 2025Source: BMJ Mental Health
Longitudinal Associations of Electroconvulsive Therapy with All-Cause Mortality and Suicide Deaths in Severe Unipolar or Bipolar Depression: A Systematic Review and Meta-Analysis
- October 30, 2025Source: eClinical Medicine
Analysis: Efficacy of Intranasal Esketamine Versus rTMS for Treatment-Resistant Depression
- September 16, 2025Source: World Psychiatry
Beyond Symptom Improvement: Transdiagnostic and Disorder-Specific Ways to Assess Functional and Quality of Life Outcomes Across Mental Disorders in Adults
Get In Touch
Copy Link
Contacts
Email